Device Trial Radar · NCT01960361
A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant
Last checked: Nov 20, 2026Latest source record: Jul 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Planned (sponsor's estimate)
Start
Jan 2015
Primary completion
Mar 2019
Study completion Jun 2019
Sponsor
- Lead sponsor
- Alpha - Bio Tec Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current prospective clinical study's aim is to determine ABT's ICE implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of ICE implants.
Conditions
- Implant Clinical Survival
- Dental Implant Bone Loss
Interventions
ICE dental implantDevice
ICE- Implant Classical Esthetic implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Survival RateTime frame: 24 MONTHS
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Assaf Harofeh Medical Center
Rishon LeZiyyon, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.